To require a report and updated guidance on continued risk management for pharmaceutical supply chains of Department of Defense.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, To require a report and updated guidance on continued risk management for pharmaceutical supply chains of Department of Defense., changes federal law or congressional policy affecting federal agencies and legislative administrators. The main policy domain is Government Operations, Healthcare, Defense.
Who Benefits and How
federal agencies and legislative administrators may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section S1: 1. Short title This Act may be cited as the Pharmaceutical Risk Assessment and Mitigation Act of 2024.
- Section id29b043b91c0748b9a1cd2e193fba7ce4: 2. Report and updated guidance on continued risk management for pharmaceutical supply chains of Department of Defense Not later than two years after the date...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, To require a report and updated guidance on continued risk management for pharmaceutical supply chains of Department of Defense., changes federal law or congressional policy affecting federal agencies and legislative administrators.
Key Policy Areas
Government Operations, Healthcare, Defense
Primary Purpose
This bill, To require a report and updated guidance on continued risk management for pharmaceutical supply chains of Department of Defense., changes federal law or congressional policy affecting federal agencies and legislative administrators.
Policy Domains
Whole bill
Identified Gains
- federal agencies and legislative administrators
Identified Costs
- federal implementing agencies
Sponsors
Gary C. Peters
D-MI | Primary Sponsor
Legislative Progress
IntroducedMr. Peters (for himself and Ms. Ernst) introduced the following …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "secretary_of_defense"
- → Secretary of Defense
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology